New Delhi News

Choroidal Neovascularization Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Choroidal Neovascularization Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

August 11
12:45 2020
Choroidal Neovascularization Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

“Choroidal Neovascularization – Market Insights, Epidemiology, and Market Forecast-2030”

(Albany, US) DelveInsight has launched a new report on Choroidal Neovascularization Market Insights, Epidemiology and Market Forecast-2030.

 

DelveInsight’s “Choroidal Neovascularization – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Choroidal Neovascularization, historical and forecasted epidemiology as well as the Choroidal Neovascularization market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the key facts of the Report:

  1. There was population burden of 41, 111 adults with myopic CNV in the United States in 2014.
  2. As per the study conducted by Jeffrey R. Willis etal. (2014), the estimated diopter-adjusted incidence of myopic CNV was 0.017% (95% CI, 0.010–0.030 among adults in the United States aged 18 years and older in 2014.The estimated point prevalence of FTD is 15 – 22/100,000, and the incidence is 2.7-4.1/100,000.
  3. The Incidence of CNV in individuals with pathologic myopia was reported to be 5.2%-11.3%, and was bilateral in approximately 15% of patients.

 

Key benefits of the Report

1. Choroidal Neovascularization market report covers a descriptive overview and comprehensive insight of the Choroidal Neovascularization epidemiology and Choroidal Neovascularization market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. Choroidal Neovascularization market report provides insights on the current and emerging therapies. 

3. Choroidal Neovascularization market report offers a global historical and forecasted market covering drug outreach in 7 MM.

4. Choroidal Neovascularization market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Choroidal Neovascularization market.

 

Request for Sample Pages: https://www.delveinsight.com/sample-request/choroidal-neovascularization-market

 

“According to DelveInsight’s analysis, Females are affected more as compared to males, in the case of Choroidal Neovascularization.”

 

Choroidal neovascularization (CNV) involves the growth of new blood vessels that originate from the choroid through a break in the Bruch membrane into the sub–retinal pigment epithelium (sub-RPE) or subretinal space. CNV is a major cause of visual loss. The symptoms of CNV include a distortion or waviness of central vision or a gray/black/void spot in the central vision.

Conditions That May Cause Choroidal Neovascularization:

• Age-related macular degeneration is the most common disease causing CNV, but other diseases that “stress” the retina, causing it to produce excess VEGF, or disrupting the barrier between the retina and choroid, can also cause CNV.

• In patients with pathologic myopia (extreme nearsightedness), the eye is longer than normal, and this lengthening stretches and stresses the retina.

• Ocular histoplasmosis is a fungal infection that can cause CNV.

• Eye trauma and angioid streaks (small breaks in one of the retina’s layers) can break the barrier between the retina and choroid, resulting in CNV.

• Severe ocular inflammation, a condition called uveitis, can also cause CNV.

• The ophthalmologist can detect CNV using a combination of techniques. First, during the dilated eye exam, she/he may see a blister of fluid or bleeding in the retina. Then, using specialized imaging called optical coherence tomography (OCT), a cross-section picture of the retina is obtained. This image can detect even small amounts of fluid that have leaked into the retina from CNV.

 

Some of the key companies working on Choroidal Neovascularization are:

  • AnewPharma
  • Iconic Therapeutics
  • Adverum Biotechnologies
  • And Many Others.

The launch of the emerging therapies is expected to significantly impact the Choroidal Neovascularization treatment scenario in the upcoming years:-

 

 Drugs Covered:

  • CM082
  • ICON-1
  • ADVM-022
  • And Many Others.

 

Request for Sample Pages: https://www.delveinsight.com/sample-request/choroidal-neovascularization-market

 

Table Of Contents:

1. Report Introduction

2. Executive Summary

3. SWOT Analysis

4. Choroidal Neovascularization Market Overview at a Glance

4.1. 7 Major Market Size of Choroidal Neovascularization in 2017

4.2. 7 Major Market Size of Choroidal Neovascularization in 2030

5. Disease Background and Overview: Choroidal Neovascularization

5.1. Introduction

5.2. Causes

5.3. Pathophysiology

5.4. Symptoms

5.5. Risk Factor

5.6. Diagnosis

6. Epidemiology and Patient Population

6.1. Assumptions and Rationale

6.2. 7MM Incident cases of Choroidal Neovascularization (2017–2030)

6.3. 7MM Cause-specific Incidence of Choroidal Neovascularization (2017–2030)

6.4. 7MM Diagnosed and Treatable Cases of Choroidal Neovascularization (2017–2030)

7. Choroidal Neovascularization: Country- Wise Epidemiology

7.1. United States

7.1.1. Incident cases of Choroidal Neovascularization in the United States (2017–2030)

7.1.2. Cause-specific Incidence of Choroidal Neovascularization (2017–2030)

7.1.3. Diagnosed and Treatable Cases of Choroidal Neovascularization in the United States (2017–2030)

7.2. EU-5

7.2.1. Germany

7.2.1.1. Incident cases of Choroidal Neovascularization in Germany (2017–2030)

7.2.1.3. Cause-specific Incidence of Choroidal Neovascularization in Germany (2017–2030)

7.2.1.3. Diagnosed and Treatable Cases of Choroidal Neovascularization in Germany (2017–2030)

7.2.2. France

7.2.2.1. Incident cases of Choroidal Neovascularization in France (2017–2030)

7.2.2.3. Cause-specific Incidence of Choroidal Neovascularization in France (2017–2030)

7.2.2.4. Diagnosed and Treatable Cases of Choroidal Neovascularization in France (2017–2030)

7.2.3. Italy

7.2.3.1. Incident cases of Choroidal Neovascularization in Italy (2017–2030)

7.2.3.3. Cause-specific Incidence of Choroidal Neovascularization in Italy (2017–2030)

7.2.3.4. Diagnosed and Treatable Cases of Choroidal Neovascularization in Italy (2017–2030)

7.2.4. Spain

7.2.4.1. Incident cases of Choroidal Neovascularization in Spain (2017–2030)

7.2.4.3. Cause-specific Incidence of Choroidal Neovascularization in Spain (2017–2030)

7.2.4.4. Diagnosed and Treatable Cases of Choroidal Neovascularization in Spain (2017–2030)

7.2.5. United Kingdom

7.2.5.1. Incident cases of Choroidal Neovascularization in the United Kingdom (2017–2030)

7.2.5.3. Cause-specific Incidence of Choroidal Neovascularization in the United Kingdom (2017–2030)

7.2.5.4. Diagnosed and Treatable Cases of Choroidal Neovascularization in the United Kingdom (2017–2030)

7.3. Japan

7.3.1. Incident cases of Choroidal Neovascularization in Japan (2017–2030)

7.3.3. Cause-specific Incidence of Choroidal Neovascularization in Japan (2017–2030)

7.3.4. Diagnosed and Treatable Cases of Choroidal Neovascularization in Japan (2017–2030)

8. Treatment & Medical Practices

8.1. Treatment Algorithm

8.2. Treatment Guidelines

9. Patient Journey

10. Marketed Drugs

10.1. Lucentis : Roche

10.1.1. Product Description

10.1.2. Regulatory Milestones

10.1.3. Advantages & Disadvantages

10.1.4. Product Profile

10.1.5. Safety and Efficacy

10.1.6. Side effects

10.2. Eylea: Regeneron Pharmaceuticals

10.2.1. Product Description

10.2.2. Regulatory Milestones

10.2.3. Advantages & Disadvantages

10.2.4. Product Profile

10.2.5. Safety and Efficacy

10.2.6. Side effects

11. Key Emerging Therapies

11.1. ADVM-022: Adverum Biotechnologies

11.1.1. Regulatory Milestones

11.1.2. Clinical Development

11.1.3. Product Profile

11.1.4. Clinical Pipeline Activity

11.1.5. Ongoing Trials Information

11.1.6. Clinical Trial by Phase

11.2. ICON-1: Iconic Therapeutics

11.2.1. Regulatory Milestones

11.2.2. Clinical Development

11.2.3. Product Profile

11.2.4. Clinical Pipeline Activity

11.2.5. Ongoing Trials Information

11.2.6. Clinical Trial by Phase

To be continued in the report………

12. Attribute Analysis

13. Choroidal Neovascularization: Market Size

13.1. Key Findings

13.2. Total 7MM Choroidal Neovascularization Market Analysis

13.2.1. Overview of Total Choroidal Neovascularization Market

13.2.2. Market size of Choroidal Neovascularization by 7MM (2017–2030)

14. 7MM Choroidal Neovascularization: Country-Wise Market Analysis

14.1. United States

14.1.1. Total Market Size of Choroidal Neovascularization

14.1.2. Market Size of Choroidal Neovascularization by Therapies

14.2. Germany

14.2.1. Total Market Size of Choroidal Neovascularization

14.2.2. Market Size of Choroidal Neovascularization by Therapies

14.3. France

14.3.1. Total Market Size of Choroidal Neovascularization

14.3.2. Market Size of Choroidal Neovascularization by Therapies

14.4. United Kingdom

14.4.1. Total Market Size of Choroidal Neovascularization

14.4.2. Market Size of Choroidal Neovascularization by Therapies

14.5. Spain

14.5.1. Total Market Size of Choroidal Neovascularization

14.5.2. Market Size of Choroidal Neovascularization by Therapies

14.6. Italy

14.6.1. Total Market Size of Choroidal Neovascularization

14.6.2. Market Size of Choroidal Neovascularization by Therapies

14.7. Japan

14.7.1. Total Market Size of Choroidal Neovascularization

14.7.2. Market Size of Choroidal Neovascularization by Therapies

15. Market Access and Reimbursement

16. Market Drivers

17. Market Barriers

18. Appendix

19. Report Methodology

19.1. Sources Used

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

 

Related Reports:

Choroidal Neovascularization – Pipeline Insights, 2020

The Choroidal Neovascularization report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Choroidal Neovascularization across the complete product development cycle, including all clinical and nonclinical stages.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/choroidal-neovascularization-market

Related Articles